2007-2008 CGR
2007-2008
Cardiovascular Medicine Grand Rounds
Sept. 11, 2007
“Relationship of Albuminuria, Estimated GFR,
and Blood Pressure with Cardiovascular Disease:
2007 Implications for Treatment”
Matthew R. Weir, M.D.
Professor of Medicine
Head of the Nephrology Division
University of Maryland
Baltimore, MD
Sept. 18, 2007
“CT Coronary Angiography:
How, When and Why to Perform?”
Mario Garcia, M.D.
Professor of Medicine in Cardiology
Professor, Radiology
Mount Sinai Medical Center
New York, NY
Sept. 25, 2007
“Comprehensive Magnetic Resonance
in Peripheral Arterial Disease”
Christopher Kramer, M.D.
Associate Professor of
Radiology and Internal Medicine
Division Head, Dept. of Radiology –
Cardiac Magnetic Resonance Imaging
University of Virginia
Charlottesville, VA
Holiday
Learning Objectives: Following the lecture, participants should be able to: Recognize the predictive value of estimated GFR and residual albuminuria in assessing CVD burden and response to therapy. Recognize the importance of lower BP goals and Renin Angiotensin Aldosterone System (RAAS) blockade on renal function and albuminuria.
evaluate whether residual albuminuria may assist in identifying optimal BP for reducing CV events perhaps related to more effective control of central aortic pressure. Evaluate newer strategies to lower BP and block the RAAS and what impact it may have on renal function, albuminuria, and CVD risk: higher dose RAAS blockade, dual RAAS blockade, aldosterone blockade, renin inhibition, etc.
Learning Objectives: Following the lecture, participants should be able to:recall technical principles of multi-detector computed tomography (MDCT)
recognize clinical applications of MDCT coronary angiography
recognize limitations and risks of cardiac MDCT
Learning Objectives: Following the lecture, participants should be able to:identify how multi-modality MR can be used to assess peripheral arterial disease
evaluate imaging predictors of functional capacity in peripheral arterial disease
identify how MR endpoints can be used in clinical trials in peripheral arterial disease
Oct. 2, 2007
“Takayasu’s Arteritis”
Kenneth Cherry, M.D.
Professor of Surgery
Division of Thoracic and Cardiovascular Surgery
University of Virginia
Charlottesville, VA
Oct. 9, 2007
“Nuclear Cardiology and Cardiac CT:
Which Test for Which Patient”
Daniel S. Berman, M.D.
Chief of Cardiac Imaging and Nuclear Cardiology
S. Mark Taper Foundation Imaging Center
Cedars Sinai Medical Center
Los Angeles, CA
Oct. 16, 2007
“The Regression of Atherosclerosis:
an Achievable Goal?”
Edward A. Fisher, M.D., Ph.D.
Adjunct Professor, Medicine
Adjunct Professor, Pediatrics
Adjunct Professor,
Molecular, Cell and Developmental Biology
Adjunct Professor,
Center For Anatomy and Functional Morphology
Mount Sinai Medical Center
New York, NY
Oct. 23, 2007
“Coronary Magnetic Resonance Imaging (MRI)”
Warren Manning, M.D.
Chief, Non-Invasive Cardiac Imaging
Co-Director, Cardiac MR Center
Assistant Professor of Medicine, Harvard Medical School
Professor of Radiology, Harvard Medical School
Boston, MA
Oct. 30, 2007
“Unwrapping the Enigma of
Ischemic Mitral Regurgitation”
John Dent, M.D.
Associate Professor of Medicine
Director, Echocardiography and Exercise Stress
Director, Cardiovascular Fellowship Program
University of Virginia
Charlottesville, VA
Learning Objectives: Following the lecture, participants should be able to:
What is Takayasu’s arteritis?
What arteries are usually involved?
What is the medical management of these patients?
Who requires operation, and what results may be expected?
Learning Objectives: Following the lecture, participants should be able to:
describe the strengths and weaknesses of cardiac CT and Nuclear Cardiology
recognize which test is most helpful in various settings
evaluate the situations in which the different modalities provide complementary information.
Learning Objectives: Following the lecture, participants should be able to:
recognize how mice can be used as models of human atherosclerosis
correlate data from mouse models and clinical studies to support the hypothesis that human plaques can be regressed.
Learning Objectives: Following the lecture, participants should be able to:
recognize the obstacles to coronary MRI
recognize the current role of coronary MRI
anticipate future advances in coronary MRI
Learning Objectives: Following the lecture, participants should be able to:
recognize why use of the phrase “papillary muscle dysfunction” should be avoided
identify the clinical significance of mitral regurgitation associated with coronary artery disease
identify some of the mechanisms of ischemic mitral regurgitation
Nov. 13, 2007
The 7th Annual Richard Savington
Crampton Lecture
“Personalized Medicine –
An Idea Whose Time is Approaching”
Robert Roberts, M.D.
President, Chief Executive Officer
and Chief Scientific Officer,
University of Ottawa Heart Institute
Ottawa, CANADA
Nov. 20, 2007
“Modern Treatment of Ventricular Tachycardia”
David Cesario, M.D., Ph.D.
Assistant Professor of Medicine
University of California
Los Angeles, CA
Nov. 27, 2007
“Measuring Wall Motion to Diagnose Ischemia
and Asynchrony: A Common Language for Cardiologists and Engineers”
Jeffrey W. Holmes, Ph.D., M.D., UCSD
Associate Professor of
Biomedical Engineering and Medicine
University of Virginia
Charlottesville, VA
American Heart Association Conference
No CGR
Learning Objectives: Following the lecture, participants should be able to:
recall the basics of human genetics
recognize the ethical and social concerns of human genetics
evaluate the fundamental issues involved with personalized medicine based on the individual’s genetic makeup.
Learning Objectives: Following the lecture, participants should be able to:
recognize the major indications for ICD therapy
recall current approaches to ablation of ventricular tachycardia.
identify potential future therapies for VT.
Learning Objectives: Following the lecture, participants should be able to:
identify existing technical barriers to quantitative analysis of wall motion and understand why three-dimensional imaging overcomes some of these barriers.
determine why different measures of regional mechanics, such as strain, strain rate, and wall motion, may have different sensitivity in detecting regional ischemia.
recognize similarities between deformation in ischemic and late-activated asynchronous myocardium.
“Critical Issues in the Development
of ACC/AHA Practice Guidelines”
Sidney C. Smith, Jr., M.D.
Professor of Medicine
Director, Center for Cardiovascular Science and Medicine
University of North Carolina
Chapel Hill, NC
identify: the current LDL-C targets for patients with CAD, especially those with ACS and the current debate surrounding use of biomarkers and early high dose statins in treatment of patients with ACS
recognize the basis and variation in evidence for treatment of patients with ACS using ACEI therapy
recognize the indications for dual antiplatelet therapy in patients with ACS – especially those undergoing placement of drug eluting stents
“Cardiac CT: Where We Are and
Where We May Be Going”
Arthur Stillman, M.D., Ph.D.
Professor of Radiology
Director, Division of Cardiothoracic Radiology
The Emory University Health System
Atlanta, GA
identify non coronary applications of cardiac CT
recognize how CTA may be used for both acute and stable chest pain
recognize the benefits and limitations of duel source and 256-slice MDCT
“Best Practices for Managing Ischemic Stroke”
J. Claude Hemphill, M.D.
Director, Neurocritical Care Service
San Francisco General Hospital
San Francisco, CA
No CGR
No CGR
“Optimal Care in CAD: the Evolving Role of Revascularization and Medical Therapy”
Judith Hochman, M.D.
Harold Snyder Family Professor of Cardiology
Director, Cardiovascular Clinical Research Center
New York University School of Medicine
New York, NY
recognize the experimental and observational evidence for the early and late open artery hypothesis
evaluate the process of adverse LV remodelling post MI, risk factors, and consequences
identify the appropriate role for late revascularization post MI based on the findings of OAT
“Peripheral Arterial Disease:
The Next Cardiovascular Frontier”
Mark A. Creager, M.D.
Director, Vascular Center
Brigham and Women’s Hospital
Boston, MA
identify the epidemiology and prognostic implications of peripheral arterial disease
discuss the diagnostic evaluation of peripheral arterial disease
evaluate pharmacologic and revascularization strategies for the treatment of peripheral arterial disease
“Diabetes and Vascular Disease:
All Things Considered”
Steven P. Marso, M.D.
Associate Professor of Medicine
University of Missouri
St. Luke’s Hospital
Kansas City, MO
recognize the epidemiology of heart disease, relevant modifiable risk factors, and treatment approaches
differentiate the biologic roles of both LDL-C and HDL-C in terms of their impact on atherosclerotic burden
describe the importance of HDL-C as an independent CV risk factor
identify the cardiac imaging tools (ie, IVUS, CIMT) used to assess atherosclerotic burden and their clinical relevance in selecting and monitoring patients at risk for CV disease
outline therapeutic approaches to the management of patients with multiple types of dyslipidemias
“Percutaneous Approaches
to Mitral Valve Disease””
D. Scott Lim, M.D.
Assistant Professor of Clinical Pediatrics
University of Virginia
Charlottesville, VA
describe the evaluation and percutaneous balloon valvuloplasty of rheumatic mitral stenosis
identify options for percutaneous repair of paravalvar mitral leaks
discuss the ongoing trial for percutaneous repair of mitral regurgitation
“Mitral Valve Surgery”
Irving L. Kron, M.D.
S. Hurt Watts, Professor of Surgery and Chair
Division of Thoracic and Cardiovascular Surgery
University of Virginia
Charlottesville, VA
describe the mechanisms of mitral regurgitation
identify the surgical indications for mitral valve repair
“VTE/PE Prophylaxis and Treatment:
An Urgent Call to Action for a Common
but Preventable Disease”
Anthony J. Comerota, M.D., FACS, RVT
Director, Jobst Vascular Center
Toledo, OH
Clinical Professor of Surgery
University of Michigan
Ann Arbor, MI
describe the current treatment guidelines for prophylaxis and management of venous thromboembolism (VTE) and pulmonary embolism (PE) in the high-risk hospitalized patient, with such well-established risk factors such as acute illness, cancer, and infection, and those who are undergoing a surgical procedure
identify the strengths and weaknesses of the data supporting individual guideline recommendations for the high-risk hospitalized patient
assess currently available therapeutic strategies for patients at high risk of developing VTE
explain the risks and benefits of individual treatment options as they pertain to different high-risk patient populations
“Smoking Cessation”
Scott Strayer, MD, MPH
Associate Professor of Family Medicine
University of Virginia
Charlottesville, VA
describe the latest evidence for treatments during smoking cessation, including the use of tricyclic anti-depressants in adults and patches in adolescents.
discuss the key components of “Motivational Interviewing” and the “Stages of Change” and how they are used in smoking cessation counseling.
identify web-based and computer resources that assist physicians with smoking cessation counseling.
identify web-based and computer resources that assist patients with smoking cessation.
“Overview of the Randomized Cell Therapy Clinical Trials for Chronic Ischemia and AMI – Why are the Efficacy Signals Still Weak?” ”
Stephen E. Epstein, M.D.
Executive Director, Cardiovascular Research Institute
Hyattsville, MD
Director, Vascular Biology Research,
MedStar Research Institute,
Washington Hospital Center,
Washington, D.C.
“Holey Stroke! – The Role of a Patent Foramen
Ovale (PFO) and Cerebral Ischemic Stroke”
Nina J. Solenski, M.D.
Associate Professor of Neurology
Department of Neurology
University of Virginia
Charlottesville, VA
“Id3 and Vascular Disease”
Coleen McNamara, M.D.
Associate Professor,
Cardiovascular Division
University of Virginia
Charlottesville, VA
identify the initiating cellular mechanisms of atherosclerosis development.
identify animal model approaches for studying atherosclerosis initiation and progression.
describe the role of adipocytes in atherosclerosis.
“Targeted Imaging Using Contrast
Echocardiography Techniques”
Flordeliza S. Villanueva, M.D.
Co-Director, Cardiac CT Program
Director, Center for Ultrasound Molecular
Imaging and Therapeutics
Director, Noninvasive Cardiac Imaging
University of Pittsburgh
Pittsburgh, PA
identify general principles of contrast echocardiography.
discuss research in the use of targeted imaging agents to study cardiovascular physiology and pathophysiology.
“Biomaterials and Cells for Infarct Repair”
Jonathan Leor, M.D.
Director, Neufield Cardiac Research Institute
Tel-Aviv University
Sheba Medical Center
Tel-Hashomer, ISRAEL
identify the promises and pitfalls of cell therapy for myocardial regeneration.
identify problems and hurdles in myocardial repair.
discuss novel concepts regarding myocardial repair.
American College of Cardiology
Conference
“Change of Hearts: NCEP III Guidelines
for Primary Prevention and Beyond”
Kwame Akosah, M.D.
Associate Professor of Internal Medicine
Division of Cardiovascular Medicine
University of Virginia
Charlottesville, VA
identify key concepts of NCEP III guidelines for prevention.
discuss the strengths and limitations of the guidelines.
evaluate the role of imaging modalities in CHD prevention.
“Drug Eluting Stents: 2008”
George W. Vetrovec, M.D.
Kimmerling Professor of Medicine and
Chair of Cardiology
VCU Pauley Heart Center
Medical College of Virginia Campus
Virginia Commonwealth University
Richmond, VA
identify factors that increase adverse outcomes for BMS and DES stents.
describe the relative risk of complex coronary anatomy on stent outcomes.
discuss the role of antiplatelet agents on preventing late stent thrombosis
The Twenty-Fourth Annual
Marjorie and Jaye Grollman
Visiting Lectureship in Cardiology
“Unraveling the Mysteries of Diastole ”
Rick A. Nishimura, M.D.
Leighton Professor of
Cardiovascular Diseases and Hypertension
Mayo Medical School
Associate Chair of Lifelong Learning
Program Director of the Cardiovascular
Diseases Fellowship Training Program
Mayo Clinic
Rochester, MN
identify the pathophysiology of diastolic filling of the LV
determine the optimal treatment for the patient with heart failure and normal EF
utilize noninvasive methods to understand phases of diastolic dysfunction
[one_fifith]April 29, 2008
“Cardiovascular MRI in Hemodialysis Patients”
Brian Schietinger, M.D.
Cardiovascular Fellow
University of Virginia
Charlottesville, VA[/one_fifth]
identify the cardiovascular risk of this patient population.
describe the cardiovascular MRI findings in this patient population.
define the disorder nephrogenic systemic fibrosis (NSF).
“Erectile Dysfunction: a Barometer
of Cardiovascular Health”
Hemant Solomon, M.D.
Cardiovascular Fellow
University of Virginia
Charlottesville, VA
describe the association of ED and coronary disease
identify the cardiovascular prognostic implications of ED
identify the cardiovascular medications which are associated with ED
“Peripheral Arterial Disease: New Concepts
in Diagnosis and Treatment”
Justin Anderson, M.D.
Cardiovascular Fellow
University of Virginia
Charlottesville, VA
describe the morbidity and mortality implications of PAD
identify the pathophysiology of claudication
describe the limitations of therapeutic trials in PAD
discuss potential novel endpoints in PAD therapeutic trials
“The Role of Oxidized Phospholipids in
Mediating Lp(a) Atherogenicity”
Sotirios “Sam” Tsimikas, M.D.,
FACC, FAHA, FSCAI
Professor of Clinical Medicine
Director of Vascular Medicine
University of California San Diego
School of Medicine
Associate Editor of JACC
San Diego, CA
discuss the evidence for the hypothesis that the atherogenicity of Lp(a) is due, in part, to its unique ability to bind pro-inflammatory OxPL
“Anticoagulation for Atrial Fibrillation:
Topics of Contention”
Raj Subramanian, M.D.
Cardiovascular Fellow
University of Virginia
Charlottesville, VA
consider who is a good candidate for warfarin
identify the bleeding risks
evaluate the use of warfarin for the very elderly
discuss warfarin dosage decisions
discuss anticoagulation in patients with AF and stable coronary disease
discuss anticoagulation in patients with AF and recent PCI.
“Updates in the Management of
Resistant Hypertension”
Dave Y. Chua, M.D.
Cardiovascular Fellow
University of Virginia
Charlottesville, VA
identify the clinical consequences of hypertension
discuss the implications from recent hypertension studies
outline a treatment strategy for resistant hypertension
describe new developments in hypertension research
“Improving Outcomes in Sudden Cardiac Arrest”
Aalya Crowl, M.D.
Cardiovascular Fellow
University of Virginia
Charlottesville, VA
identify use and impact of AEDs in public and private settings
describe mechanism of therapeutic hypothermia
discuss UVA protocol for therapeutic hypothermia
“Carotid Artery Disease:
Who should we screen?
How do we treat it?”
Susan Lane, M.D., Ph.D.
Cardiovascular Fellow
University of Virginia
Charlottesville, VA
identify risk factors and significance of carotid artery stenosis
describe who should be screened and how to screen for carotid artery stenosis
discuss how to treat carotid artery stenosis once diagnosed (medical therapy, CEA, CAS)